Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome

Gail J. Roboz; Ellen K. Ritchie; Tania Curcio; Michael Samuel; Juliette Provenzano; Javier Segovia; Paul J. Christos; Susan Mathew; Sandra Allen-Bard; Eric J. Feldman

doi:10.1016/j.leukres.2010.09.010

Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome

Gail J. Roboz, Ellen K. Ritchie, Tania Curcio, Michael Samuel, Juliette Provenzano, Javier Segovia, Paul J. Christos, Susan Mathew, Sandra Allen-Bard, Eric J. Feldman

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate-2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.

Original language	English (US)
Pages (from-to)	522-525
Number of pages	4
Journal	Leukemia Research
Volume	35
Issue number	4
DOIs	https://doi.org/10.1016/j.leukres.2010.09.010
State	Published - Apr 2011
Externally published	Yes

Keywords

Arsenic
Low-dose cytarabine
MDS
Myelodysplastic syndrome

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2010.09.010

Cite this

@article{b77a2ae6b9e0493694a54f058e2b1754,

title = "Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome",

abstract = "Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate-2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.",

keywords = "Arsenic, Low-dose cytarabine, MDS, Myelodysplastic syndrome",

author = "Roboz, {Gail J.} and Ritchie, {Ellen K.} and Tania Curcio and Michael Samuel and Juliette Provenzano and Javier Segovia and Christos, {Paul J.} and Susan Mathew and Sandra Allen-Bard and Feldman, {Eric J.}",

year = "2011",

month = apr,

doi = "10.1016/j.leukres.2010.09.010",

language = "English (US)",

volume = "35",

pages = "522--525",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome

AU - Roboz, Gail J.

AU - Ritchie, Ellen K.

AU - Curcio, Tania

AU - Samuel, Michael

AU - Provenzano, Juliette

AU - Segovia, Javier

AU - Christos, Paul J.

AU - Mathew, Susan

AU - Allen-Bard, Sandra

AU - Feldman, Eric J.

PY - 2011/4

Y1 - 2011/4

N2 - Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate-2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.

AB - Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate-2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.

KW - Arsenic

KW - Low-dose cytarabine

KW - MDS

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=79952359646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952359646&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2010.09.010

DO - 10.1016/j.leukres.2010.09.010

M3 - Article

C2 - 20956016

AN - SCOPUS:79952359646

SN - 0145-2126

VL - 35

SP - 522

EP - 525

JO - Leukemia Research

JF - Leukemia Research

IS - 4

ER -

Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this